Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00824668
NCT00824668CompletedPhase 1

A Randomised, Open-labelled, 2-period Crossover Trial Investigating Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 Thrice Daily and Basal-bolus Therapy With Insulin Glargine & Insulin Glulisine in Subjects With Type 2 Diabetes

Novo Nordisk A/S2 sites in 1 country24 target enrollmentStarted: August 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
24
Locations
2
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This trial is conducted in Europe. The aim of this clinical trial is to compare the 24-hour pharmacodynamics/ pharmacokinetics of biphasic insulin aspart 30 (BiAsp 30) thrice daily treatment with that of a basal-bolus treatment with insulin glargine and insulin glulisine in type 2 diabetic subjects.

Pharmacodynamics is the glucose-lowering effect of the study medication over the entire observation phase from the time of administration and the efficacy period while the pharmacokinetics is the amount of the study insulin that can be determined in the blood.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Type 2 diabetes mellitus for 12 months or longer
  • •Body Mass Index (BMI): 25.0-40.0 kg/m2, both inclusive
  • •HbA1c between 7.0 and 10.5% at screening
  • •Insulin treatment for at least 3 months prior to screening with a total daily dose of 0.6 and 0.9 U/kg body weight

Exclusion Criteria

  • •Use of any oral antidiabetic agent within the past 2 months
  • •Cardiac disease: NYHA class III or IV chronic heart failure (CHF), unstable angina, and/or any myocardial infarction (treated or untreated) within 6 months prior to screening
  • •Hepatic insufficiency (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or greater than 2 times the central laboratory's upper reference limit)
  • •Renal insufficiency (serum creatinine equal to or greater than 1.6 mg/dL for males; equal to or greater than 1.4 mg/dL for females)
  • •Recurrent hypoglycaemia
  • •Anaemia (haemoglobin less than 13.0 mg/dL in males and less than 12.0 mg/dL in females; WHO-criteria)
  • •Use of concomitant medications (prescribed or non-prescribed and other than insulin) which may alter glucose metabolism including but not limited to: systemic or inhaled glucocorticoids, anabolic steroids, non-selective beta-blockers

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 1
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 DiabetesDiabetes Mellitus, Type 2Diabetes
NCT00825253Novo Nordisk A/S24
Completed
Phase 1
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1
NCT01536028Novo Nordisk A/S32
Completed
Phase 1
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy VolunteersHealthyDiabetes
NCT01707160Novo Nordisk A/S24
Completed
Phase 1
Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT01497561Novo Nordisk A/S15
Completed
Phase 3
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT01520753Novo Nordisk A/S16